Abstract：Objective: To compare the difference of clinical efficacy between BCH-2003 program and CCLG-2008 regimen in the diagnosis of acute lymphoblastic leukemia (molecular marker TEL-AML1), so as to provide reference for clinical children to choose appropriate diagnosis and treatment plan according to the actual condition. Methods: From August 2012 to December 2015, 120 cases of children with acute lymphoblastic leukemia who were hospitalized for chemotherapy in our hospital were enrolled in the study. They were treated by BCH-2003 program and CCLG-2008 program. The children in each group were 60 cases, respectively. The molecular biological markers were TEL-AML1. The statistical differences in the recurrence of the two groups, the plasma related biochemical indexes (VEGF, VEGFR, bFGF, MVD), and the clinical efficacy were compared. Results: The changes of VEGF, VEGFR, bFGF and MVD were significantly changed (P<0.05) before and after treatment in the two groups. After treatment, the differences of VEGF, VEGFR and MVD in the two groups were statistically significant (p<0.05). The difference of clinical efficacy between the two groups was statistically significant (P<0.05). The difference of adverse reactions between the two groups was statistically significant (P<0.05). The difference of the risk of recurrence of the two groups was statistically significant (P<0.05), and the difference of the immunophenotype of the two groups was statistically significant (P<0.05). The recurrence of the two groups was compared, and the differences in risk, immune classification and recurrence were statistically significant (all P<0.05). Conclusions: The short term clinical efficacy of the BCH-2003 regimen is better than the CCLG-2008 scheme in the treatment of children with TEL-AML1 fusion gene positive acute lymphoblastic leukemia. However, the incidence of adverse reactions and the severity of relapse in the CCLG-2008 regimen were better than that of the BCH-2003 regimen.
2018, Vol. 24 
冀公网安备13080202000677号